Forge announces presentations at upcoming scientific and industry meetings
2018 BIO International, ASM Microbe, and GRC Metals in Medicine San Diego, California, May 21, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology [...]
Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting
San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]
Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference
-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, [...]
Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting
San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor [...]
Forge expands footprint with new office and lab space in Torrey Mesa, San Diego
-"What it Means to be Handcrafted in San Diego" Open House Event to Commemorate New Space- San Diego, California, March 12, 2018 – Forge [...]
Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference
-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]
Forge therapeutics announces participation in upcoming scientific and industry events
San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]
-
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas GalleryForge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships – [...]
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to present at World Anti-Microbial Resistance Congress 2017
San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., (Forge) announced today that the company will present a talk entitled, “Forging new [...]